Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 58,766 | 62,472 | 57,336 | 46,497 | 37,428 |
| Cost of Goods | 9,383 | 9,919 | 7,625 | 20,364 | 14,161 |
| Gross Profit | 49,383 | 52,553 | 49,711 | 26,133 | 23,267 |
| Operating Expenses | 45,317 | 39,383 | 36,822 | 40,803 | 35,933 |
| Operating Income | 4,449 | 14,089 | 13,514 | -14,306 | -12,505 |
| Interest Expense | 4,748 | 6,834 | 7,770 | 6,877 | 6,661 |
| Other Income | 1,454 | -7,008 | 368 | -1,621 | -873 |
| Pre-tax Income | 1,155 | 247 | 6,112 | -22,804 | -20,039 |
| Income Tax | 615 | N/A | N/A | N/A | N/A |
| Net Income Continuous | 540 | 247 | 6,112 | -22,804 | -20,039 |
| Net Income | $540 | $247 | $6,112 | $-22,804 | $-20,039 |
| EPS Basic Total Ops | 0.00 | 0.00 | 0.03 | -0.10 | -0.10 |
| EPS Basic Continuous Ops | 0.00 | 0.00 | 0.03 | -0.11 | -0.10 |
| EPS Diluted Total Ops | 0.00 | 0.00 | 0.03 | -0.10 | -0.10 |
| EPS Diluted Continuous Ops | 0.00 | 0.00 | 0.03 | -0.11 | -0.10 |
| EPS Diluted Before Non-Recurring Items | 0.00 | 0.00 | 0.03 | -0.10 | -0.10 |
| EBITDA(a) | $4,767 | $14,405 | $13,828 | $-763 | $-3,131 |